Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • ERS Guidelines
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • ERS Guidelines
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Subscriptions

Effect of aclidinium bromide on dyspnoea and health status in patients with stable COPD: Phase III data by GOLD 2013 classification

Robert M. Mróz, Maria Pilar Ausin, Rosa Lamarca, Esther Garcia Gil
European Respiratory Journal 2014 44: P891; DOI:
Robert M. Mróz
1Department of Lung Diseases and Tuberculosis, Medical University of Bialystok, Bialystok, Poland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Maria Pilar Ausin
2IMIM. UPF. CIBERE, Hospital del Mar, Barcelona, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rosa Lamarca
3R&D Centre, Almirall, Barcelona, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Esther Garcia Gil
3R&D Centre, Almirall, Barcelona, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
Loading

Abstract

Background

Current GOLD guidelines classify patients with COPD into groups (A–D) in terms of less or more symptoms and low or high risk. Long-acting muscarinic antagonists, such as aclidinium, are now recommended as first-choice option for Group B–D patients and as an alternative choice for Group A patients.

Aim

To assess the effect of aclidinium 400 µg twice daily (BID) on dyspnoea and health status in patients with COPD stratified by GOLD group.

Methods

Data from the placebo and aclidinium arms of three, 6-month, placebo-controlled studies evaluating aclidinium mono- or combination-therapy in patients with moderate-to-severe COPD were analysed. Breathlessness was assessed using the Transitional Dyspnoea Index (TDI) and health status using the St George's Respiratory Questionnaire (SGRQ). Health status assessment was based on two studies due to a treatment interaction by study (p<0.05).

Results

In total, 1787 patients were included: baseline characteristics (mean ranges) age 62.4–63.9 years, mean FEV1 % predicted 54–57%, percentage of patients in each group was A: 7.9%, B: 48.4%, C: 3.1%, D: 40.6 %. At Week 24, aclidinium significantly improved TDI and SGRQ total scores vs placebo (overall and Groups A+C and B+D; see Table).

Conclusions

Aclidinium improved dyspnoea and health status regardless of GOLD Group.

Figure
  • Download figure
  • Open in new tab
  • Download powerpoint

  • Bronchodilators
  • COPD - management
  • © 2014 ERS
Previous
Back to top
Vol 44 Issue Suppl 58 Table of Contents
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Effect of aclidinium bromide on dyspnoea and health status in patients with stable COPD: Phase III data by GOLD 2013 classification
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Effect of aclidinium bromide on dyspnoea and health status in patients with stable COPD: Phase III data by GOLD 2013 classification
Robert M. Mróz, Maria Pilar Ausin, Rosa Lamarca, Esther Garcia Gil
European Respiratory Journal Sep 2014, 44 (Suppl 58) P891;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Effect of aclidinium bromide on dyspnoea and health status in patients with stable COPD: Phase III data by GOLD 2013 classification
Robert M. Mróz, Maria Pilar Ausin, Rosa Lamarca, Esther Garcia Gil
European Respiratory Journal Sep 2014, 44 (Suppl 58) P891;
Reddit logo Technorati logo Twitter logo Connotea logo Facebook logo Mendeley logo

Jump To

  • Article
  • Figures & Data
  • Info & Metrics
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

  • Budesonide/formoterol maintenance and reliever therapy in adolescent patients with asthma
  • Maintenance of IRF1 by MAPK inhibition: A mechanism by which DUSP1 reduces glucocorticoid inhibition of CXCL10
  • Increased expression of ADRB2, CHRM3 and glucocorticoid alpha receptor genes in blood leukocytes of COPD patients
Show more 5.1 Airway Pharmacology and Treatment

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2023 by the European Respiratory Society